⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Rugen Therapeutics (Rugen Biomed) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Rugen Therapeutics (Rugen Biomed)
↗Boston, USA / Suzhou, China
Rugen Therapeutics is a biotechnology company focused on the discovery and development of novel, first-in-class small molecule drugs for central nervous system (CNS) disorders, including psychiatric indications such as autism spectrum disorders (ASD), obsessive-compulsive disorders (OCD), and treatment-resistant depression. The company utilizes proprietary technology based on circuit mechanisms of psychiatric disorders and genetic-based animal models to identify therapeutic candidates.
Founded in 2013, the company has operated with research facilities in Suzhou, China (BioBay) and has maintained a corporate presence in Boston, MA. It has historically been backed by the F-Prime Biomedical Research Initiative (FBRI) and has engaged in strategic collaborations with major pharmaceutical companies like Allergan and Otsuka (via the McQuade Center for Strategic Research and Development).
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Venture Capital-Backed
Investors:F-Prime Capital
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Allergan (Collaboration for ASD/OCD), Otsuka / McQuade Center for Strategic Research and Development (Collaboration for treatment-resistant depression)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Stacie Weninger - Chair of the Board
Jay Liu - Founder/Lead Scientist
LINKS
Website:rugenbiomed.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Rugen Therapeutics (Rugen Biomed). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.